Leerink analyst Christopher Liu downgraded Ideaya Biosciences (IDYA) to Market Perform from Outperform with a $27 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- IDEAYA Biosciences: Q3 2024 Financial and Clinical Progress
- Ideaya Biosciences reports Q3 EPS (60c), consensus (63c)
- Ideaya Biosciences announces IND clearance for Werner Helicase inhibitor
- Ideaya Biosciences announces IDE397 expansion data
- Verizon downgraded, Canadian Pacific upgraded: Wall Street’s top analyst calls